Ontology highlight
ABSTRACT:
SUBMITTER: Sharma S
PROVIDER: S-EPMC5356593 | biostudies-literature | 2016 Oct
REPOSITORIES: biostudies-literature
Sharma Shruti S Galanina Natalie N Guo Ailin A Lee Jimmy J Kadri Sabah S Van Slambrouck Charles C Long Bradley B Wang Weige W Ming Mei M Furtado Larissa V LV Segal Jeremy P JP Stock Wendy W Venkataraman Girish G Tang Wei-Jen WJ Lu Pin P Wang Yue Lynn YL
Oncotarget 20161001 42
Ibrutinib (ibr), a first-in-class Bruton tyrosine kinase (BTK) inhibitor, has demonstrated high response rates in both relapsed/refractory and treatment naïve chronic lymphocytic leukemia (CLL). However, about 25% of patients discontinue ibrutinib therapy at a median follow-up of 20 months and many patients discontinue the treatment due to leukemia progression or Richter transformation. Mutations affecting the C481 residue of BTK disrupt ibrutinib binding and have been characterized by us and ot ...[more]